Wyeth

Zx Pharma, LLC

Soci&#xc9;t&#xc9; Des Produits Nestl&#xc9; S.a.

Physician's Seal, LLC

Societe Des Produits Nestle S.a.

Wyeth Holdings Corporation

Solvay Pharmaceuticals, B.v.

American Home Products Corporation

Pfizer Corporation

Progenics Pharmaceuticals, Inc.

Progenics Pharmamceuticals, Inc.

Société Des Produits Nestlé S.a.

Syed Muzafar Shah

Daniel Hassan

Fred Hassan

Mahdi Bakir Fawzi

Christopher Richard Diorio

Jonathan Marc Cohen

Panolil C Raveendranath

Mahdi B Fawzi

Tianmin Zhu

Christian Ofslager

Eric C Ehrnsperger

Nataliya Bazhina

Kadum A Al Shareffi

Galen W Radebaugh

Sreenivasulu Megati

John Lokhnauth

Huyi Zhang

Steven R Fabian

Charles Melucci

George Joseph Donato, Iii

Niketa Patel

Jan Szeliga

Kadum A Ali

Sripriya Venkata Ramana Rao

Xu Meng

Michael Z Kagan

Sarah Hassan

Richard William Saunders

Arwinder Singh Nagi

Noreen Hassan

Hanumantharao Tatapudy

Shailesh Singh

Sumon A Hasan

Patrick Corsino

Valeriya N Smolenskaya

Horace Fletcher, Iii

Anthony Francis Hadfield

Julio Perez

Michael William Winkley

Subodh S Deshmukh

Thomas A Boyd

Leonard Alexander McDonald

James Andrew Provost

Xuejun Tang

George O Morton

Fangming Kong

Maja Vencl-Joncic

Eugene Murphy

Beat Theodor Weber

Joseph Zeldis

Mark A Collins

Reinhold H Bender

Mahmoud Mirmehrabi

Reinhold H W Bender

Aeri Park

Karen Sutherland

Wendy Ann Dulin

FangMing Kong

Brenton William Russell

Rex Alwyn Shipplett

Charles T Gombar

Rex A Shipplett

Christopher Diorio

Karen Wiggins Sutherland

Christian Luther Ofslager

Arwinder Nagi

Kadum Abdul Al-Shareffi

Kadum A Al-Shareffi

Kadum A Shareffi

Natalyia Bazhina

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

Formulations for parenteral delivery of compounds and uses thereof

Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.

Oral solid cannabinoid oil composition for treating gastrointestinal disorders

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

Multiparticulate L-carnitine compositions and related methods

A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.

Enteric coated multiparticulate compositions with a proteinaceous subcoat

An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.

Multiparticulate L-menthol formulations and related methods

A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.

Dosage form with sustained release melatonin pellets

A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.

Valerian composition and related methods

An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.

Controlled-release melatonin compositions and related methods

A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.

Method of making an L-menthol dosage form

A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 &#x3bc;m to 270 &#x3bc;m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/mto 130 g/m. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 &#x3bc;m to 30 &#x3bc;m.

Packaging for solid dosage forms of melatonin with a high citric acid concentration

A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.

Growing community of inventors

East Hanover, NJ, United States of America

Syed Muzafar Shah